SEC Form 4 · accession 0001209191-17-050586
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Emil D Kakkis
Officer — President & CEO · Director
Period of report
Aug 28, 2017
Accepted (ET)
Aug 29, 2017 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 28, 2017 | P | 5,853 | $52.40 | A | 2,558,094 | I | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
| Common StockF2 | Aug 28, 2017 | P | 1,647 | $52.96 | A | 2,559,741 | I | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
| Common Stock | holding | — | — | — | 430,569 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $51.89 to $52.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $52.90 to $52.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.